Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception

Renee Heffron, Nelly Mugo, Edwin Were, James Kiarie, Elizabeth A. Bukusi, Andrew Mujugira, Lisa M. Frenkel, Deborah Donnell, Allan Ronald, Connie Celum, Jared M. Baeten, L. F. Robert W. Coombs, Uganda Kabwohe, Uganda Jinja, Craig W. Hendrix, Jairam Lingappa, M. Juliana McElrath, Eldoret Kenya, Kenneth Fife, Elioda TumwesigyeUganda Kampala, A. R. Elly Katabira, Kenya Kisumu, Uganda Mbale, Kenya Nairobi, Patrick Ndase, Elly Katabira, Craig Cohen, Jonathan Wangisi, James Campbell, Jordan Tappero, Kenya Thika, Uganda Tororo, Carey Farquhar, Grace John-Stewart, Nelly Rwamba Mugo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA. Design: Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples. Methods: PrEP efficacy for HIV-1 prevention was compared among HIV-1-uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1-infected female partners used DMPA versus no hormonal contraception. Results: Of 4747 HIV-1 serodiscordant couples, 901 HIV-1-uninfected women used DMPA at some point during follow-up, 1422 HIV-1-uninfected women used no hormonal contraception, 1568 HIV-1-uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared with placebo, were similar among women using DMPA and those using no hormonal contraception (64.7 and 75.5%, adjusted interaction P=0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0 versus 81.7%, adjusted interaction P=0.52). Conclusion: PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1.

Original languageEnglish (US)
Pages (from-to)2771-2776
Number of pages6
JournalAIDS
Volume28
Issue number18
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Medroxyprogesterone Acetate
Contraception
HIV-1
Tenofovir
Placebos
Heterosexuality

Keywords

  • Depot medroxyprogesterone acetate
  • HIV-1 prevention
  • Hormonal contraception
  • Preexposure prophylaxis efficacy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Heffron, R., Mugo, N., Were, E., Kiarie, J., Bukusi, E. A., Mujugira, A., ... Mugo, N. R. (2014). Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS, 28(18), 2771-2776. https://doi.org/10.1097/QAD.0000000000000493

Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. / Heffron, Renee; Mugo, Nelly; Were, Edwin; Kiarie, James; Bukusi, Elizabeth A.; Mujugira, Andrew; Frenkel, Lisa M.; Donnell, Deborah; Ronald, Allan; Celum, Connie; Baeten, Jared M.; Robert W. Coombs, L. F.; Kabwohe, Uganda; Jinja, Uganda; Hendrix, Craig W.; Lingappa, Jairam; McElrath, M. Juliana; Kenya, Eldoret; Fife, Kenneth; Tumwesigye, Elioda; Kampala, Uganda; Elly Katabira, A. R.; Kisumu, Kenya; Mbale, Uganda; Nairobi, Kenya; Ndase, Patrick; Katabira, Elly; Cohen, Craig; Wangisi, Jonathan; Campbell, James; Tappero, Jordan; Thika, Kenya; Tororo, Uganda; Farquhar, Carey; John-Stewart, Grace; Mugo, Nelly Rwamba.

In: AIDS, Vol. 28, No. 18, 2014, p. 2771-2776.

Research output: Contribution to journalArticle

Heffron, R, Mugo, N, Were, E, Kiarie, J, Bukusi, EA, Mujugira, A, Frenkel, LM, Donnell, D, Ronald, A, Celum, C, Baeten, JM, Robert W. Coombs, LF, Kabwohe, U, Jinja, U, Hendrix, CW, Lingappa, J, McElrath, MJ, Kenya, E, Fife, K, Tumwesigye, E, Kampala, U, Elly Katabira, AR, Kisumu, K, Mbale, U, Nairobi, K, Ndase, P, Katabira, E, Cohen, C, Wangisi, J, Campbell, J, Tappero, J, Thika, K, Tororo, U, Farquhar, C, John-Stewart, G & Mugo, NR 2014, 'Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception', AIDS, vol. 28, no. 18, pp. 2771-2776. https://doi.org/10.1097/QAD.0000000000000493
Heffron, Renee ; Mugo, Nelly ; Were, Edwin ; Kiarie, James ; Bukusi, Elizabeth A. ; Mujugira, Andrew ; Frenkel, Lisa M. ; Donnell, Deborah ; Ronald, Allan ; Celum, Connie ; Baeten, Jared M. ; Robert W. Coombs, L. F. ; Kabwohe, Uganda ; Jinja, Uganda ; Hendrix, Craig W. ; Lingappa, Jairam ; McElrath, M. Juliana ; Kenya, Eldoret ; Fife, Kenneth ; Tumwesigye, Elioda ; Kampala, Uganda ; Elly Katabira, A. R. ; Kisumu, Kenya ; Mbale, Uganda ; Nairobi, Kenya ; Ndase, Patrick ; Katabira, Elly ; Cohen, Craig ; Wangisi, Jonathan ; Campbell, James ; Tappero, Jordan ; Thika, Kenya ; Tororo, Uganda ; Farquhar, Carey ; John-Stewart, Grace ; Mugo, Nelly Rwamba. / Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. In: AIDS. 2014 ; Vol. 28, No. 18. pp. 2771-2776.
@article{f5c1e38e7f434d58ae3c8197e5970e6a,
title = "Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception",
abstract = "Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA. Design: Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples. Methods: PrEP efficacy for HIV-1 prevention was compared among HIV-1-uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1-infected female partners used DMPA versus no hormonal contraception. Results: Of 4747 HIV-1 serodiscordant couples, 901 HIV-1-uninfected women used DMPA at some point during follow-up, 1422 HIV-1-uninfected women used no hormonal contraception, 1568 HIV-1-uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared with placebo, were similar among women using DMPA and those using no hormonal contraception (64.7 and 75.5{\%}, adjusted interaction P=0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0 versus 81.7{\%}, adjusted interaction P=0.52). Conclusion: PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1.",
keywords = "Depot medroxyprogesterone acetate, HIV-1 prevention, Hormonal contraception, Preexposure prophylaxis efficacy",
author = "Renee Heffron and Nelly Mugo and Edwin Were and James Kiarie and Bukusi, {Elizabeth A.} and Andrew Mujugira and Frenkel, {Lisa M.} and Deborah Donnell and Allan Ronald and Connie Celum and Baeten, {Jared M.} and {Robert W. Coombs}, {L. F.} and Uganda Kabwohe and Uganda Jinja and Hendrix, {Craig W.} and Jairam Lingappa and McElrath, {M. Juliana} and Eldoret Kenya and Kenneth Fife and Elioda Tumwesigye and Uganda Kampala and {Elly Katabira}, {A. R.} and Kenya Kisumu and Uganda Mbale and Kenya Nairobi and Patrick Ndase and Elly Katabira and Craig Cohen and Jonathan Wangisi and James Campbell and Jordan Tappero and Kenya Thika and Uganda Tororo and Carey Farquhar and Grace John-Stewart and Mugo, {Nelly Rwamba}",
year = "2014",
doi = "10.1097/QAD.0000000000000493",
language = "English (US)",
volume = "28",
pages = "2771--2776",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception

AU - Heffron, Renee

AU - Mugo, Nelly

AU - Were, Edwin

AU - Kiarie, James

AU - Bukusi, Elizabeth A.

AU - Mujugira, Andrew

AU - Frenkel, Lisa M.

AU - Donnell, Deborah

AU - Ronald, Allan

AU - Celum, Connie

AU - Baeten, Jared M.

AU - Robert W. Coombs, L. F.

AU - Kabwohe, Uganda

AU - Jinja, Uganda

AU - Hendrix, Craig W.

AU - Lingappa, Jairam

AU - McElrath, M. Juliana

AU - Kenya, Eldoret

AU - Fife, Kenneth

AU - Tumwesigye, Elioda

AU - Kampala, Uganda

AU - Elly Katabira, A. R.

AU - Kisumu, Kenya

AU - Mbale, Uganda

AU - Nairobi, Kenya

AU - Ndase, Patrick

AU - Katabira, Elly

AU - Cohen, Craig

AU - Wangisi, Jonathan

AU - Campbell, James

AU - Tappero, Jordan

AU - Thika, Kenya

AU - Tororo, Uganda

AU - Farquhar, Carey

AU - John-Stewart, Grace

AU - Mugo, Nelly Rwamba

PY - 2014

Y1 - 2014

N2 - Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA. Design: Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples. Methods: PrEP efficacy for HIV-1 prevention was compared among HIV-1-uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1-infected female partners used DMPA versus no hormonal contraception. Results: Of 4747 HIV-1 serodiscordant couples, 901 HIV-1-uninfected women used DMPA at some point during follow-up, 1422 HIV-1-uninfected women used no hormonal contraception, 1568 HIV-1-uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared with placebo, were similar among women using DMPA and those using no hormonal contraception (64.7 and 75.5%, adjusted interaction P=0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0 versus 81.7%, adjusted interaction P=0.52). Conclusion: PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1.

AB - Objective: To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA. Design: Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples. Methods: PrEP efficacy for HIV-1 prevention was compared among HIV-1-uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1-infected female partners used DMPA versus no hormonal contraception. Results: Of 4747 HIV-1 serodiscordant couples, 901 HIV-1-uninfected women used DMPA at some point during follow-up, 1422 HIV-1-uninfected women used no hormonal contraception, 1568 HIV-1-uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared with placebo, were similar among women using DMPA and those using no hormonal contraception (64.7 and 75.5%, adjusted interaction P=0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0 versus 81.7%, adjusted interaction P=0.52). Conclusion: PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1.

KW - Depot medroxyprogesterone acetate

KW - HIV-1 prevention

KW - Hormonal contraception

KW - Preexposure prophylaxis efficacy

UR - http://www.scopus.com/inward/record.url?scp=84927748449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927748449&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000493

DO - 10.1097/QAD.0000000000000493

M3 - Article

C2 - 25493602

AN - SCOPUS:84927748449

VL - 28

SP - 2771

EP - 2776

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 18

ER -